敬修堂品牌怎么样 申请店铺

我要投票 敬修堂在生发行业中的票数:757 更新时间:2026-02-07
敬修堂是哪个国家的品牌?「敬修堂」是 广州白云山敬修堂药业股份有限公司 旗下著名品牌。该品牌发源于广东,由创始人梁铭基在1992-12-01期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力敬修堂品牌出海!将品牌入驻外推网,定制敬修堂品牌推广信息,可以显著提高敬修堂产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

敬修堂怎么样

广州敬修堂(药业)股份有限公司是广州医药集团有限公司、广州药业股份有限公司(香港H股和上海A股大型上市公司)下属的主要中成药制造企业之一。始创于1790年(清乾隆五十四年),是国家商务部认定的“中华老字号”企业。1992年12月改制为股份有限公司,是广州市首批转制的国有工业企业。公司获得澳大利亚TGA认证,是广东省率先通过国家GMP认证的中成药制造企业。

“敬业修明、广施妙药”是敬修堂创始人钱树田倡导的传统经营宗旨。公司生产各类中成药、化学药、保健滋补品共10个剂型140多个品种。产品疗效卓著,久享盛誉,深受海内外患者和消费者欢迎。其中追风透骨丸、中风回春丸、清热消炎宁胶囊、化痔栓、跌打万花油、养血生发胶囊列入国家中药保护品种,十几个产品被评为省、市名牌优质产品。化痔栓秘方、跌打万花油秘方被列入广东省第一批岭南中药文化遗产保护名录。公司自2004年涉足日化产业,主要有中药化妆品、口腔用品等。

公司推行“以市场为先导,以质量为准则,以科技提升企业,以管理创造效益”的经营方针。建立扁平化的营销架构,培育精干的营销队伍,维护忠实的客户资源。内部实施ERP、LIMS&SOP、OA、E-HR等信息化管理系统。重视科技投入,视质量为生命,开展药材GAP基地、指纹图谱质量检测、药材CO2超临界萃取等技术研究,其中“指纹图谱质量检测研究及其药材GAP示范基地建设”荣获广州市科学技术进步二等奖。公司积极与各大高校和科研机构合作,不断开展中药新技术研究和新产品开发。其中,被列为广州市中药现代化重大研究专项之一的“清热消炎宁物质基础与作用机理研究”项目在2007年取得了重大科研突破,首次发现了清热消炎宁不仅具有广谱抗菌作用,而且能够提高人体的免疫力。2008年,公司被认定为广东省第一批高新技术企业,清热消炎宁胶囊、追风透骨丸和跌打万花油被认定为高新技术产品。专业化、专家化、品牌化是公司的发展战略,敬修堂致力打造为“风湿跌打痹症类用药全国专业品牌”和“清热类用药区域首选品牌”。

“务实、创新、进取、和谐”的企业精神体现了新时期企业和员工共同的价值追求。敬修堂将一如既往,大力弘扬中药传统文化,积极发展中药现代科技,用自己的努力回报社会、服务客户、满足消费者,也为“敬修堂”开创更美好的明天,为“园田”结出更丰硕的成果。

Guangzhou jingxiutang (pharmaceutical) Co., Ltd. is one of the main Chinese patent medicine manufacturing enterprises under Guangzhou Pharmaceutical Group Co., Ltd. and Guangzhou Pharmaceutical Co., Ltd. (Hong Kong H-share and Shanghai A-share large listed companies). Founded in 1790 (the 54th year of Qianlong's reign in the Qing Dynasty), it is a "Chinese time-honored brand" enterprise recognized by the Ministry of Commerce of the people's Republic of China. In December 1992, it was restructured into a joint stock limited company. It is one of the first batch of state-owned industrial enterprises in Guangzhou. The company has obtained TGA certification in Australia, and is the first Chinese patent medicine manufacturer in Guangdong Province to pass GMP certification. The traditional management tenet advocated by Qian Shutian, the founder of Jingxiu hall, is to "devote oneself to work and cultivate wisdom, and widely apply magic medicine". The company produces more than 140 varieties of 10 dosage forms of various Chinese patent medicine, chemical medicine and health tonic. The product has outstanding curative effect and long enjoyed a good reputation. It is welcomed by patients and consumers at home and abroad. Among them, zhuofengtougu pill, Zhongfeng Huichun pill, Qingre xiaoyanning capsule, HuaZhiShuan, Dida Wanhua oil and Yangxue Shengfa capsule are listed in the national traditional Chinese medicine protection varieties, and more than ten products are rated as provincial and municipal famous high-quality products. HuaZhiShuan secret recipe and Dieda wanhuayou secret recipe were listed in the first batch of Lingnan traditional Chinese medicine cultural heritage protection list in Guangdong Province. Since 2004, the company has been involved in the daily chemical industry, mainly including traditional Chinese medicine cosmetics, oral products, etc. The company carries out the management policy of "taking the market as the guide, taking the quality as the criterion, improving the enterprise with science and technology, and creating benefits with management". Establish a flat marketing structure, cultivate a capable marketing team, and maintain loyal customer resources. Internal implementation of ERP, LIMS & SOP, OA, e-HR and other information management systems. Pay attention to scientific and technological investment, regard quality as life, carry out technical research on GAP base of traditional Chinese medicine, quality detection of fingerprint, supercritical CO2 extraction of traditional Chinese medicine, among which "quality detection of fingerprint and construction of gap demonstration base of traditional Chinese medicine" won the second prize of Guangzhou Science and Technology Progress Award. The company actively cooperates with universities and scientific research institutions to continuously carry out new technology research and new product development of traditional Chinese medicine. Among them, as one of the major research projects in the modernization of traditional Chinese medicine in Guangzhou, "Research on the material basis and mechanism of Qingre xiaoyanning" project made a major scientific breakthrough in 2007. It was found for the first time that Qingre xiaoyanning not only has a broad-spectrum antibacterial effect, but also can improve the immunity of human body. In 2008, the company was recognized as the first batch of high-tech enterprises in Guangdong Province, and Qingre xiaoyanning capsule, zhuofengtougu pill and Dieda Wanhua oil were recognized as high-tech products. Professional, expert and brand are the development strategies of the company. Jingxiutang is committed to building a "national professional brand of rheumatic and debilitating arthralgia drugs" and "first choice brand of Qingre drugs". The spirit of "pragmatic, innovative, enterprising and harmonious" embodies the common value pursuit of enterprises and employees in the new era. Jingxiutang will, as always, vigorously promote traditional Chinese medicine culture, actively develop modern technology of traditional Chinese medicine, use its own efforts to repay the society, serve customers and meet consumers, and create a better tomorrow for jingxiutang and produce more fruitful results for Yuantian.

本文链接: https://brand.waitui.com/c1210837c.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

央行等八部门:在境内开展现实世界资产代币化活动,应予以禁止

36氪获悉,中国人民银行等八部门发布关于进一步防范和处置虚拟货币等相关风险的通知。其中提到,现实世界资产代币化是指使用加密技术及分布式账本或类似技术,将资产的所有权、收益权等转化为代币(通证)或者具有代币(通证)特性的其他权益、债券凭证,并进行发行和交易的活动。在境内开展现实世界资产代币化活动,以及提供有关中介、信息技术服务等,涉嫌非法发售代币票券、擅自公开发行证券、非法经营证券期货业务、非法集资等非法金融活动,应予以禁止;经业务主管部门依法依规同意,依托特定金融基础设施开展的相关业务活动除外。境外单位和个人不得以任何形式非法向境内主体提供现实世界资产代币化相关服务。

50分钟前

央行等八部门:金融机构不得为虚拟货币相关业务活动提供账户开立、资金划转和清算结算等服务

36氪获悉,中国人民银行等八部门发布关于进一步防范和处置虚拟货币等相关风险的通知。其中提到,通知指出,强化对金融、中介、技术等服务机构的管理。金融机构(含非银行支付机构)不得为虚拟货币相关业务活动提供账户开立、资金划转和清算结算等服务,不得发行和销售虚拟货币相关金融产品,不得将虚拟货币及相关金融产品纳入抵质押品范围,不得开展与虚拟货币相关的保险业务或将虚拟货币纳入保险责任范围,并加强风险监测,发现违法违规问题线索应及时向相关部门报告。金融机构(含非银行支付机构)不得为未经同意的现实世界资产代币化相关业务以及相关金融产品提供托管、清算结算等服务。有关中介机构、信息技术服务机构不得为未经同意的现实世界资产代币化相关业务以及相关金融产品提供中介、技术等服务。

50分钟前

央行等八部门:任何单位和个人投资虚拟货币、现实世界资产代币及相关金融产品,损失由其自行承担

36氪获悉,中国人民银行等八部门发布关于进一步防范和处置虚拟货币等相关风险的通知。通知指出,违反本通知规定开展虚拟货币、现实世界资产代币化相关非法金融活动,以及为虚拟货币、现实世界资产代币化相关业务提供服务的,依照有关规定予以处罚;构成犯罪的,依法追究刑事责任。对于明知或应知境外主体非法向境内提供虚拟货币、现实世界资产代币化相关服务,仍为其提供协助的境内单位和个人,依法追究有关责任;构成犯罪的,依法追究刑事责任。任何单位和个人投资虚拟货币、现实世界资产代币及相关金融产品,违背公序良俗的,相关民事法律行为无效,由此引发的损失由其自行承担;涉嫌破坏金融秩序、危害金融安全的,由相关部门依法查处。

50分钟前

中国人民银行、中国证监会有关负责人就《关于进一步防范和处置虚拟货币等相关风险的通知》答记者问

36氪获悉,中国人民银行、中国证监会有关负责人就《关于进一步防范和处置虚拟货币等相关风险的通知》答记者问。关于虚拟货币,长期以来,境内始终对虚拟货币相关业务活动保持禁止性的政策立场。2013年,中国人民银行等五部门联合印发《关于防范比特币风险的通知》,明确比特币是一种特定的虚拟商品,不能且不应作为货币在市场上流通使用。2021年印发的《关于进一步防范和处置虚拟货币交易炒作风险的通知》进一步明确,比特币、以太币,以及泰达币等稳定币,均不具有与法定货币等同的法律地位,在境内开展虚拟货币相关业务活动属于非法金融活动,一律严格禁止。《通知》延续了近年来的政策立场,重申虚拟货币不具有与法定货币等同的法律地位,在境内开展虚拟货币相关业务活动属于非法金融活动,境外单位和个人不得以任何形式非法向境内主体提供虚拟货币相关服务。

50分钟前

分子之心MoleculeOS完成重大代际升级

36氪获悉,近日,分子之心宣布其AI蛋白质优化与设计平台MoleculeOS完成重大代际升级。同时,分子之心依托NewOrigin(达尔文)创新算法,解决了AlphaFold 3等模型无法解决的产业难题。

50分钟前

本页详细列出关于敬修堂的品牌信息,含品牌所属公司介绍,敬修堂所处行业的品牌地位及优势。
咨询